MedTrace Logo

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-10-24

No results posted yet for this study

Summary

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

Conditions

Interventions

DRUG

ERX1000

ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension

DRUG

Placebo

A suspension containing magnesium hydroxide carbonate in polysorbate

Sponsors & Collaborators

  • ERX Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Irene Mirkin, MD · Labcorp Clinical Research Unit Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2023-07-03
Completion
2023-07-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04890873 on ClinicalTrials.gov